# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-21-055589
Filing Date
2021-04-27
Accepted
2021-04-27 16:06:06
Documents
3
Period of Report
2021-06-17

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm212386-1_def14a.htm | DEF 14A | 1130079
2 | GRAPHIC | tm212386d1-proxy_cellpg1bw.jpg | GRAPHIC | 462166
3 | GRAPHIC | tm212386d1-proxy_cellpg2bw.jpg | GRAPHIC | 338808
| Complete submission text file | 0001104659-21-055589.txt |  | 2233358

Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-15006 | Film No.: 21858925
SIC: 2835 In Vitro & In Vivo Diagnostic Substances